| ●Editorial | Planning Editorial Committee of the Future of Obstetric Medicine | 220 |
| ●What is the future of obstetric medicine? | ||
| Assisted Reproduction Technology and gonadotropins | Rimkus KH, Ogawa A | 221-30 |
| Assisted Reproduction Technology and gonadotropins−Discussion | Rimkus KH, et al. | 231-52 |
| The discussion for oral contraceptive | Yamanaka S | 253-84 |
| The discussion for oral contraceptive−Discussion | Yamanaka S, et al. | 285-98 |
| The right and the shadow of obstetric medicine | Horiguchi S | 299-313 |
| The right and the shadow of obstetric medicine−Discussion | Horiguchi S, et al. | 315-28 |
| ●Articles | ||
| The French research participants protection regulations in 2006 (3) Compensation, registry, indemnity and perspective of participant protection | Nudeshima J | 329-35 |
| Hypocrisy of medical journals: death merchants selling leading journals | Saio T, Kurihara C, Mitsuishi T, et al. | 337-43 |
| ●Material | ||
| Translation of EMEA/CHMP/96268/2005/Guideline on Risk Management Systems for Medicinal Products for Human | Barata K, Furukawa A, Ishida K, et al. | 345-6 |
| Guideline on Risk Management Systems for Medicinal Products for Human Use | Committee for Medicinal Products for Human Use（CHMP） （trans. by Saio T, Kurihara C, Pharmacovigilance Working Group） | 347-74 |
| ●Forum | ||
| Medicinal Chemist, the Artist in Pharmaceutical R&D, Open the Door to the Future | Itoh K | 375-8 |
| ●Instructions for authors [English] | 379-84 | |
| ●Editor's note | Saio T | 385 |